Natural history of urine and plasma oxalate in children with primary hyperoxaluria type 1.
Genetic variants
Primary hyperoxaluria
Urinary stone disease
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
received:
27
03
2023
accepted:
22
06
2023
revised:
13
06
2023
medline:
27
11
2023
pubmed:
17
7
2023
entrez:
17
7
2023
Statut:
ppublish
Résumé
Primary hyperoxaluria type 1 (PH1) is a rare, severe genetic disease causing increased hepatic oxalate production resulting in urinary stone disease, nephrocalcinosis, and often progressive chronic kidney disease. Little is known about the natural history of urine and plasma oxalate values over time in children with PH1. For this retrospective observational study, we analyzed data from genetically confirmed PH1 patients enrolled in the Rare Kidney Stone Consortium PH Registry between 2003 and 2018 who had at least 2 measurements before age 18 years of urine oxalate-to-creatinine ratio (Uox:cr), 24-h urine oxalate excretion normalized to body surface area (24-h Uox), or plasma oxalate concentration (Pox). We compared values among 3 groups: homozygous G170R, heterozygous G170R, and non-G170R AGXT variants both before and after initiating pyridoxine (B6). Of 403 patients with PH1 in the registry, 83 met the inclusion criteria. Uox:cr decreased rapidly over the first 5 years of life. Both before and after B6 initiation, patients with non-G170R had the highest Uox:cr, 24-h Uox, and Pox. Patients with heterozygous G170R had similar Uox:cr to homozygous G170R prior to B6. Patients with homozygous G170R had the lowest 24-h Uox and Uox:cr after B6. Urinary oxalate excretion and Pox tend to decrease over time during childhood. eGFR over time was not different among groups. Children with PH1 under 5 years old have relatively higher urinary oxalate excretion which may put them at greater risk for nephrocalcinosis and kidney failure than older PH1 patients. Those with homozygous G170R variants may have milder disease. A higher resolution version of the Graphical abstract is available as Supplementary information.
Sections du résumé
BACKGROUND
BACKGROUND
Primary hyperoxaluria type 1 (PH1) is a rare, severe genetic disease causing increased hepatic oxalate production resulting in urinary stone disease, nephrocalcinosis, and often progressive chronic kidney disease. Little is known about the natural history of urine and plasma oxalate values over time in children with PH1.
METHODS
METHODS
For this retrospective observational study, we analyzed data from genetically confirmed PH1 patients enrolled in the Rare Kidney Stone Consortium PH Registry between 2003 and 2018 who had at least 2 measurements before age 18 years of urine oxalate-to-creatinine ratio (Uox:cr), 24-h urine oxalate excretion normalized to body surface area (24-h Uox), or plasma oxalate concentration (Pox). We compared values among 3 groups: homozygous G170R, heterozygous G170R, and non-G170R AGXT variants both before and after initiating pyridoxine (B6).
RESULTS
RESULTS
Of 403 patients with PH1 in the registry, 83 met the inclusion criteria. Uox:cr decreased rapidly over the first 5 years of life. Both before and after B6 initiation, patients with non-G170R had the highest Uox:cr, 24-h Uox, and Pox. Patients with heterozygous G170R had similar Uox:cr to homozygous G170R prior to B6. Patients with homozygous G170R had the lowest 24-h Uox and Uox:cr after B6. Urinary oxalate excretion and Pox tend to decrease over time during childhood. eGFR over time was not different among groups.
CONCLUSIONS
CONCLUSIONS
Children with PH1 under 5 years old have relatively higher urinary oxalate excretion which may put them at greater risk for nephrocalcinosis and kidney failure than older PH1 patients. Those with homozygous G170R variants may have milder disease. A higher resolution version of the Graphical abstract is available as Supplementary information.
Identifiants
pubmed: 37458799
doi: 10.1007/s00467-023-06074-x
pii: 10.1007/s00467-023-06074-x
doi:
Substances chimiques
Oxalates
0
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
141-148Subventions
Organisme : RDCRN
ID : U54DK83908
Informations de copyright
© 2023. The Author(s), under exclusive licence to International Pediatric Nephrology Association.
Références
Sas DJ, Harris PC, Milliner DS (2019) Recent advances in the identification and management of inherited hyperoxalurias. Urolithiasis 47:79–89
doi: 10.1007/s00240-018-1093-3
pubmed: 30535828
Hopp K, Cogal AG, Bergstralh EJ et al (2015) Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 26:2559–2570
doi: 10.1681/ASN.2014070698
pubmed: 25644115
pmcid: 4587693
Harambat J, Fargue S, Acquaviva C et al (2010) Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome. Kidney Int 77:443–449
doi: 10.1038/ki.2009.435
pubmed: 20016466
Stenson PD, Ball EV, Mort M et al (2003) Human gene mutation database (HGMD): 2003 update. Hum Mutat 21:577–581
doi: 10.1002/humu.10212
pubmed: 12754702
Danpure CJ (2006) Primary hyperoxaluria type 1: AGT mistargeting highlights the fundamental differences between the peroxisomal and mitochondrial protein import pathways. Biochim Biophys Acta 1763:1776–1784
doi: 10.1016/j.bbamcr.2006.08.021
pubmed: 17027096
Monico CG, Rossetti S, Olson JB, Milliner DS (2005) Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 67:1704–1709
doi: 10.1111/j.1523-1755.2005.00267.x
pubmed: 15840016
Harambat J, van Stralen KJ, Espinosa L et al (2012) Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol 7:458–465
doi: 10.2215/CJN.07430711
pubmed: 22223608
pmcid: 3302673
Lieske JC, Monico CG, Holmes WS et al (2005) International registry for primary hyperoxaluria. Am J Nephrol 25:290–296
doi: 10.1159/000086360
pubmed: 15961949
Schwartz GJ, Munoz A, Schneider MF et al (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637
doi: 10.1681/ASN.2008030287
pubmed: 19158356
pmcid: 2653687
Ladwig PM, Liedtke RR, Larson TS, Lieske JC (2005) Sensitive spectrophotometric assay for plasma oxalate. Clin Chem 51:2377–2380
doi: 10.1373/clinchem.2005.054353
pubmed: 16306102
Wilson DM, Liedtke RR (1991) Modified enzyme-based colorimetric assay of urinary and plasma oxalate with improved sensitivity and no ascorbate interference: reference values and sample handling procedures. Clin Chem 37:1229–1235
doi: 10.1093/clinchem/37.7.1229
pubmed: 1855295
Clifford-Mobley O, Tims C, Rumsby G (2015) The comparability of oxalate excretion and oxalate:creatinine ratio in the investigation of primary hyperoxaluria: review of data from a referral centre. Ann Clin Biochem 52:113–121
doi: 10.1177/0004563214529937
pubmed: 24719216
Gibbs DA, Watts RW (1969) The variation of urinary oxalate excretion with age. J Lab Clin Med 73:901–908
pubmed: 4891815
Matos V, Van Melle G, Werner D, Bardy D, Guignard JP (1999) Urinary oxalate and urate to creatinine ratios in a healthy pediatric population. Am J Kidney Dis 34:e1
doi: 10.1016/S0272-6386(99)70380-X
pubmed: 10430995
Garrelfs S, van Harskamp D, Peters-Sengers H et al (2021) Endogenous oxalate production in primary hyperoxaluria type 1 patients. J Am Soc Nephrol 32:3175–3186
doi: 10.1681/ASN.2021060729
pubmed: 34686543
pmcid: 8638398
Shah RJ, Vaughan LE, Enders FT, Milliner DS, Lieske JC (2020) Plasma oxalate as a predictor of kidney function decline in a primary hyperoxaluria cohort. Int J Mol Sci 21:3608
doi: 10.3390/ijms21103608
pubmed: 32443777
pmcid: 7279271
Zhao F, Bergstralh EJ, Mehta RA et al (2016) Predictors of incident ESRD among patients with primary hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol 11:119–126
doi: 10.2215/CJN.02810315
pubmed: 26656319
Mandrile G, van Woerden CS, Berchialla P et al (2014) Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int 86:1197–1204
doi: 10.1038/ki.2014.222
pubmed: 24988064
Lorenz EC, Lieske JC, Seide BM, Olson JB, Mehta R, Milliner DS (2021) Recovery from dialysis in patients with primary hyperoxaluria type 1 treated with pyridoxine: a report of 3 cases. Am J Kidney Dis 77:816–819
doi: 10.1053/j.ajkd.2020.07.017
pubmed: 32891627
Cellini B, Lorenzetto A, Montioli R, Oppici E, Voltattorni CB (2010) Human liver peroxisomal alanine:glyoxylate aminotransferase: different stability under chemical stress of the major allele, the minor allele, and its pathogenic G170R variant. Biochimie 92:1801–1811
doi: 10.1016/j.biochi.2010.08.005
pubmed: 20713123
Fargue S, Rumsby G, Danpure CJ (2013) Multiple mechanisms of action of pyridoxine in primary hyperoxaluria type 1. Biochim Biophys Acta 1832:1776–1783
doi: 10.1016/j.bbadis.2013.04.010
pubmed: 23597595
Singh P, Chebib FT, Cogal AG, Gavrilov DK, Harris PC, Lieske JC (2020) Pyridoxine responsiveness in a type 1 primary hyperoxaluria patient with a rare (atypical) AGXT gene mutation. Kidney Int Rep 5:955–958
doi: 10.1016/j.ekir.2020.04.004
pubmed: 32518881
pmcid: 7270974
Dindo M, Conter C, Oppici E, Ceccarelli V, Marinucci L, Cellini B (2019) Molecular basis of primary hyperoxaluria: clues to innovative treatments. Urolithiasis 47:67–78
doi: 10.1007/s00240-018-1089-z
pubmed: 30430197
Oppici E, Fargue S, Reid ES et al (2015) Pyridoxamine and pyridoxal are more effective than pyridoxine in rescuing folding-defective variants of human alanine:glyoxylate aminotransferase causing primary hyperoxaluria type I. Hum Mol Genet 24:5500–5511
doi: 10.1093/hmg/ddv276
pubmed: 26199318
Reusz GS, Dobos M, Byrd D, Sallay P, Miltenyi M, Tulassay T (1995) Urinary calcium and oxalate excretion in children. Pediatr Nephrol 9:39–44
doi: 10.1007/BF00858966
pubmed: 7742220
Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A (2005) Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl 11:1481–1493
doi: 10.1002/lt.20519
pubmed: 16315293
Paccaud Y, Rios-Leyvraz M, Bochud M et al (2020) Spot urine samples to estimate 24-hour urinary calcium excretion in school-age children. Eur J Pediatr 179:1673–1681
doi: 10.1007/s00431-020-03662-z
pubmed: 32388721
Garrelfs SF, Frishberg Y, Hulton SA et al (2021) Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med 384:1216–1226
doi: 10.1056/NEJMoa2021712
pubmed: 33789010
Milliner DS, McGregor TL, Thompson A et al (2020) End points for clinical trials in primary hyperoxaluria. Clin J Am Soc Nephrol 15:1056–1065
doi: 10.2215/CJN.13821119
pubmed: 32165440
pmcid: 7341772
Porowski T, Zoch-Zwierz W, Konstantynowicz J, Korzeniecka-Kozerska A, Michaluk-Skutnik J, Porowska H (2008) Reference values of plasma oxalate in children and adolescents. Pediatr Nephrol 23:1787–1794
doi: 10.1007/s00467-008-0889-8
pubmed: 18581146
Milliner DS, Cochat P, Hulton SA et al (2021) Plasma oxalate and eGFR are correlated in primary hyperoxaluria patients with maintained kidney function-data from three placebo-controlled studies. Pediatr Nephrol 36:1785–1793
doi: 10.1007/s00467-020-04894-9
pubmed: 33515281
pmcid: 8172484